G1 Therapeutics, Inc.
GTHXDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Trilaciclib Phase 2 Est. Readout
Estimated primary completion for Trilaciclib trial (NCT06027268) in Metastatic Triple-Negative Breast Cancer. Topline data typically follows completion by weeks to months.
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Trilaciclib
TNBC - Triple-Negative Breast Cancer
Trilaciclib, carboplatin, etoposide，or Topotecan
Extensive-stage Small-cell Lung Cancer
G1T38
Carcinoma, Non-Small-Cell Lung
Cylophosphamide
Triple Negative Breast Cancer
Lurbinectedin
Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trilaciclib | Phase 3 | TNBC - Triple-Negative Breast Cancer | - | - |
Trilaciclib, carboplatin, etoposide，or Topotecan | Phase 3 | Extensive-stage Small-cell Lung Cancer | - | - |
G1T38 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Cylophosphamide | Phase 2 | Triple Negative Breast Cancer | - | - |
Lurbinectedin | Phase 2 | Lung Cancer | - | - |
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Triple Negative Breast Cancer
1 drug in this indication
TNBC - Triple-Negative Breast Cancer
1 drug in this indication
Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in G1 Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in G1 Therapeutics, Inc.'s (GTHX) pipeline across Phase 3, Phase 2. Its lead program is Trilaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is G1 Therapeutics, Inc.'s next FDA catalyst?→
G1 Therapeutics, Inc.'s (GTHX) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GTHX biotech catalysts?→
Add GTHX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow G1 Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.